Arid4a Suppresses Breast Tumor Metastasis by Enhancing MTSS1 Expression via <scp>mRNA</scp> Stability

Pengfei Wan, Dandan Zhang, Xueting Liu, Wenbao LuCancer 2025 · DOI

TL;DR

This study reveals that the protein Arid4a acts as a suppressor of breast cancer metastasis by stabilizing the mRNA of key metastasis-suppressing genes, particularly MTSS1. This discovery highlights Arid4a as a potential therapeutic target for combating breast cancer spread.

What Problem Does This Paper Address?

Tumor metastasis is a major cause of cancer-related deaths, yet the intricate molecular mechanisms that control this process remain incompletely understood. While the role of gene expression in metastasis is well-established, the post-transcriptional regulation of metastasis-related genes, particularly by RNA-binding proteins (RBPs), has been less explored. This paper investigates the function of Arid4a, an RBP, in breast cancer metastasis, aiming to elucidate its mechanism of action and its potential as a therapeutic target.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatic Analysis: Publicly available datasets (TCGA, CPTAC) were analyzed to assess Arid4a expression levels in breast tumors and their correlation with patient prognosis and clinical features like nodal metastasis.
  • In Vitro Experiments:
    • Cell Culture: Various human breast cancer cell lines (MDA-MB-231, MDA-MB-468, MCF7, T47D) and normal mammary epithelial cells (MCF-10A, MCF-12A) were used.
  • Gene Expression Analysis: qRT-PCR was used to quantify mRNA levels.
  • Protein Analysis: Immunoblotting and immunohistochemistry (IHC) were employed to assess protein expression.
  • Functional Assays: Wound healing assays and Transwell cell invasion assays were conducted to evaluate cell migration and invasion capabilities. Cell cycle analysis was performed using flow cytometry.
  • Mechanism Elucidation: * PCR Array: A Human Tumor Metastasis PCR Array was used to screen for metastasis-related genes affected by Arid4a.
  • RNA Immunoprecipitation (RIP): RIP assays were performed to identify direct RNA targets of Arid4a.
  • Luciferase Reporter Assays: The 3' untranslated regions (3' UTRs) of target genes were cloned downstream of a luciferase gene to assess Arid4a's regulatory effect.
  • mRNA Stability Assays: Actinomycin D and 5,6-dichlorobenzimidazole riboside were used to block new mRNA synthesis, followed by RNA extraction and qRT-PCR to measure mRNA decay rates.
  • RNA Electrophoretic Mobility Shift Assay (EMSA): To investigate direct binding of Arid4a to RNA structures.
  • RIP-Chromatin Immunoprecipitation (RIP-ChIP): To confirm in vivo binding of Arid4a to specific RNA structures.
  • In Vivo Experiments:
    • Animal Models: Nude mice were used to study tumor growth and metastasis. Arid4a knockdown cells or Arid4a-expressing adenoviruses were administered to assess Arid4a's role in tumor progression and metastasis.
  • Histopathology: Hematoxylin and eosin (H&E) staining was used to examine lung tissues for metastatic nodules.

Datasets

  • Publicly Available Datasets:
    • The Cancer Genome Atlas (TCGA) database for gene expression analysis in breast tumors.
  • Clinical Proteomic Tumor Analysis Consortium (CPTAC) for protein expression analysis.
  • PrognoScan and KMPlotter for Kaplan-Meier survival analysis.
  • TIMER2.0 and GEPIA2 for correlation analysis between Arid4a and MTSS1 expression in human breast cancer patients.
  • Newly Generated Data:
    • Expression data from human breast tumor samples and cell lines analyzed in this study.
  • Results from various in vitro and in vivo experiments detailed in the Methods section.

Key Insights and Ideas

  • Arid4a as a Metastasis Suppressor: Contrary to some previous findings in other cancers, this study strongly implicates Arid4a as a suppressor of breast cancer metastasis. Its reduced expression in tumors correlates with poor patient outcomes.
  • Stabilizing Metastasis-Suppressing mRNAs: Arid4a doesn't just affect gene expression; it specifically stabilizes the mRNA of genes that inhibit metastasis. This is a crucial post-transcriptional regulatory mechanism.
  • MTSS1 as a Key Target: The study highlights MTSS1 (Metastasis Suppressor 1) as a primary target of Arid4a. Arid4a's stabilization of MTSS1 mRNA is a direct mechanism for suppressing metastasis.
  • Structural RNA Recognition: Arid4a's interaction with mRNA is not just sequence-dependent but relies on recognizing specific secondary RNA structures (stem-loop structures) within the 3' UTR of its target mRNAs. This is a sophisticated mode of RNA binding.
  • ARID Domain is Crucial: The ARID domain of Arid4a is essential for its ability to stabilize target mRNAs and inhibit metastasis, underscoring the importance of this specific protein domain.

Key Results

  • Reduced Arid4a in Tumors: Arid4a expression is significantly lower in human breast tumors compared to normal tissues, and this low expression is linked to poorer patient survival (overall survival, relapse-free survival, distant metastasis-free survival, etc.).
  • Inhibition of Proliferation and Metastasis: Overexpression of Arid4a in breast cancer cells suppressed proliferation, migration, and invasion in vitro. Conversely, Arid4a knockdown promoted these metastatic behaviors.
  • Upregulation of Metastasis Suppressors: Arid4a overexpression led to the upregulation of metastasis-suppressing genes (MTSS1, TIMP2, RB1, PTEN) and downregulation of metastasis-promoting genes.
  • mRNA Stabilization: Arid4a significantly prolonged the half-lives of metastasis-suppressing mRNAs (MTSS1, TIMP2, RB1, PTEN) in breast tumor cells.
  • In Vivo Efficacy: Adenovirus-mediated delivery of Arid4a suppressed tumor growth and lung metastasis in mouse models.
  • Positive Correlation: Arid4a expression positively correlates with the expression of metastasis-suppressing genes, particularly MTSS1, in human breast tumors.

Limitations and Future Work

  • Mechanism of Metastasis-Promoting Gene Downregulation: The study suggests that Arid4a's downregulation of metastasis-promoting genes might be an indirect effect, as Arid4a does not directly bind to their mRNAs. Further research is needed to elucidate this indirect mechanism.
  • Angiogenesis Pathway: While TIMP2 is mentioned as a potential suppressor of tumor angiogenesis, the study did not deeply explore Arid4a's role in this pathway. Future work could investigate if Arid4a suppresses breast tumor metastasis by inhibiting angiogenesis.
  • RNA-Binding Domain Specificity: The study identified the ARID domain as critical for Arid4a's function. However, the precise molecular mechanisms by which different RNA-binding domains recognize specific structural RNAs remain an open area for further investigation.
  • Therapeutic Potential: The findings strongly suggest Arid4a as a therapeutic target. Future work could focus on developing strategies to restore or enhance Arid4a function in breast cancer patients.

Summary updated

Abstract

Arid4a was confirmed to suppress breast tumor metastasis progression by stabilizing the transcripts of tumor metastasis-suppressing genes, suggesting that Arid4a might be a potential therapeutic target for breast cancer treatment.
BibTeX
@inproceedings{wan2025arid,
  author = {Pengfei Wan and Dandan Zhang and Xueting Liu and Wenbao Lu},
  title = {{Arid4a Suppresses Breast Tumor Metastasis by Enhancing MTSS1 Expression via <scp>mRNA</scp> Stability}},
  booktitle = {Cancer},
  year = {2025},
  doi = {10.1002/cam4.70732},
}
Figure